Detalhe da pesquisa
1.
Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics.
J Invest Dermatol
; 142(7): 1912-1922.e7, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34942200
2.
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine.
Pharmaceuticals (Basel)
; 14(8)2021 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34451846
3.
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma.
Cancers (Basel)
; 12(8)2020 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32764384
4.
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.
Cell Death Dis
; 11(6): 443, 2020 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32513939